Skip to main content
SpringerLink
Log in

Schwerpunkt Tumorimmunologie des Transitionalzellkarzinoms

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Sylvester RJ, Meijden AP van der, Lamm DL (2002) Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of clinical trials. J Urol 168: 1964–1970

    Article  PubMed  CAS  Google Scholar 

  2. De Boer EC, Rooijakkers SJ, Schamhart DH, Kurth KH (2003) Cytokine gene expression in a mouse model: the first instillations with viable BCG determine the succeeding Th1-response. J Urol 170: 2004–2008

    Article  Google Scholar 

  3. Tokunaga T, Yamamoto H, Shimada S et al. (1984) Antitumor activity of deoxyribonucleic acid fraction from mycobacterium bovis BCG. J Natl Cancer Inst 72: 955–962

    PubMed  CAS  Google Scholar 

  4. Ulevitch RJ (2004) Therapeutics targeting the innate immune system. Nat Rev Immunol 4: 512–520

    Article  PubMed  CAS  Google Scholar 

  5. Hemmi H, Takeuchi O, Kawai T et al. (2000) A toll like receptor recognizes bacterial DNA. Nature 408: 740–745

    Article  PubMed  CAS  Google Scholar 

  6. Olbert P, Hegele A, Dalpke A et al. (2003) Is local immunostimulation of the bladder wall by CpG-ODN possible? First histological evidence in C3H/He-N mice. J Urol 169: 138

    Google Scholar 

  7. Olbert P, Dalpke A, Schrader AJ et al. (2004) Toll like receptor expression in MB-49 transitional cell carcinoma cells in culture. Onkologie 27: 146

    Google Scholar 

  8. Hegele A, Dalpke A, Knobloch R von et al. (2004) No direct pro-apoptotic effect of immunostimulative DNA (CpG-ODN) on MB-49 transitional cell carcinoma cells in vitro. Eur Urol Suppl 3: 211

    Google Scholar 

  9. Hegele A, Dalpke A, Barth P et al. (2004) Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model. Anticancer Res 24: 2225–2230

    PubMed  CAS  Google Scholar 

  10. Hegele A, Dalpke A, Heeg K et al. (2005) Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model. Tumour Biol 26: 274–280

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Philipps-Universität Marburg, Marburg, Deutschland

    P.J. Olbert, A.J. Schrader, A. Hegele & R. Hofmann

Authors
  1. P.J. Olbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A.J. Schrader
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Hegele
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P.J. Olbert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olbert, P., Schrader, A., Hegele, A. et al. Schwerpunkt Tumorimmunologie des Transitionalzellkarzinoms. Urologe 46, 1135–1137 (2007). https://doi.org/10.1007/s00120-007-1464-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-007-1464-9

Search

Navigation